JPS57500207A - - Google Patents

Info

Publication number
JPS57500207A
JPS57500207A JP56500918A JP50091881A JPS57500207A JP S57500207 A JPS57500207 A JP S57500207A JP 56500918 A JP56500918 A JP 56500918A JP 50091881 A JP50091881 A JP 50091881A JP S57500207 A JPS57500207 A JP S57500207A
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP56500918A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPS57500207A publication Critical patent/JPS57500207A/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/971—Capture of complex after antigen-antibody reaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
JP56500918A 1980-02-22 1981-02-18 Pending JPS57500207A (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/123,562 US4342566A (en) 1980-02-22 1980-02-22 Solid phase anti-C3 assay for detection of immune complexes

Publications (1)

Publication Number Publication Date
JPS57500207A true JPS57500207A (enExample) 1982-02-04

Family

ID=22409405

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56500918A Pending JPS57500207A (enExample) 1980-02-22 1981-02-18

Country Status (4)

Country Link
US (1) US4342566A (enExample)
EP (1) EP0046786A4 (enExample)
JP (1) JPS57500207A (enExample)
WO (1) WO1981002469A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984000421A1 (fr) * 1982-07-16 1984-02-02 Otsuka Pharma Co Ltd Procede d'analyse de complexe immun specifique d'antigene associe a des tumeurs
JPH02502586A (ja) * 1987-12-10 1990-08-16 ブリテツシユ・テレコミユニケイシヨンズ・パブリツク・リミテツド・カンパニー 光学装置

Families Citing this family (247)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849353A (en) * 1980-09-30 1989-07-18 Cornell Research Foundation, Inc. Immunocapture of enzyme inhibitor, enzyme complexes and uses thereof
JPS57501691A (enExample) * 1980-10-24 1982-09-16
US4433059A (en) * 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
FR2530818B1 (fr) * 1981-11-30 1985-12-27 Inst Technologie Surfaces Ac Procede de preparation d'un oligopeptide terminal specifique de l'antigene de surface d'un germe infectieux, determination de ce germe et dispositif pour son identification
GB2117514B (en) * 1982-03-29 1985-08-29 East Anglian Regional Health Polyvalent antiglobulin reagent
US4450231A (en) * 1982-03-31 1984-05-22 Biostar Medical Products, Inc. Immunoassay for determination of immune complexes with polymer-coated plastic base
EP0091760B1 (en) * 1982-04-09 1986-07-02 FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. Anti immune complex antibody and preparation thereof
US4642284A (en) * 1983-06-13 1987-02-10 Scripps Clinic And Research Foundation Method and system for detection of complement pathway activation
US4629694A (en) * 1983-07-12 1986-12-16 Cornell Research Foundation, Inc. Detecting and distinguishing between plasminogen activators
US4960712A (en) * 1983-11-15 1990-10-02 Scripps Clinic And Research Foundation System and method for complement pathway analysis
JPS60192263A (ja) * 1984-03-13 1985-09-30 Teijin Ltd 免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法
US4687734A (en) * 1984-06-07 1987-08-18 Chester Samuel J Immunoassay for the detection of human colon cancer using a polyclonal antibody derived from a capillary culture of tumor cells
US4672044A (en) * 1984-08-24 1987-06-09 Scripps Clinic & Research Foundation Murine monoclonal antibody combining site to human C3b receptor (CR1)
JPS6175262A (ja) * 1984-09-21 1986-04-17 Teijin Ltd 免疫複合体測定用試薬及びそれを用いた免疫複合体の測定法
DK570485D0 (da) * 1985-12-10 1985-12-10 Novo Industri As Humant conglutinin
SE452065B (sv) * 1986-04-11 1987-11-09 Ulf R Nilsson Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning
IL84160A0 (en) * 1986-10-16 1988-03-31 Vasocor Method and kit for immune complex assay
SE454812B (sv) * 1986-10-22 1988-05-30 Anders Larsson Forfarande och komposition for uppfangande av eller detektering av immunkomplex och anvendning av fagelantikroppar herfor
US4810632A (en) * 1986-12-01 1989-03-07 Scripps Clinic And Research Foundation Cell surface antigen detection method
US5176998A (en) * 1986-12-01 1993-01-05 The Scripps Research Institute Cell surface antigen detection method
US4937185A (en) * 1987-07-31 1990-06-26 The Ohio State University Research Foundation Detection of circulating antibodies to a cancer marker protein
US5086002A (en) * 1987-09-07 1992-02-04 Agen Biomedical, Ltd. Erythrocyte agglutination assay
US5583003A (en) * 1989-09-25 1996-12-10 Agen Limited Agglutination assay
US5444155A (en) * 1991-09-10 1995-08-22 The Scripps Research Institute Molecules with antibody combining sites that induce asymmetry
US5250426A (en) * 1991-10-22 1993-10-05 The Scripps Research Institute Molecules with antibody combining sites that induce asymmetry
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6124439A (en) * 1994-08-17 2000-09-26 The Rockefeller University OB polypeptide antibodies and method of making
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) * 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US20020165157A1 (en) * 1996-04-01 2002-11-07 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
IL126383A0 (en) * 1996-04-01 1999-05-09 Genentech Inc Apo-2li and apo-3 apoptosis polypeptides
JP2000515735A (ja) * 1996-07-03 2000-11-28 ジェネンテック インコーポレーテッド 肝細胞成長因子レセプターアゴニスト
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US5990281A (en) * 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
US6221621B1 (en) 1997-03-06 2001-04-24 Bard Diagnostic Sciences, Inc. Methods of screening for colorectal cancers in which a complement Factor I or related protein is associated
JP2001515589A (ja) * 1997-03-06 2001-09-18 バイオン ダイアグノスティック サイエンシーズ，インコーポレイテッド 補体レギュレーターまたはレセプタータンパク質を使用するスクリーニングおよび処置
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
DK1860187T3 (da) * 1997-05-15 2011-10-31 Genentech Inc Apo-2-receptor
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US5891646A (en) * 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
US7541151B2 (en) 1997-06-05 2009-06-02 Duke University Single-cell biosensor for the measurement of GPCR ligands in a test sample
US6528271B1 (en) 1997-06-05 2003-03-04 Duke University Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
JP2001523977A (ja) 1997-06-05 2001-11-27 ザ ユニバーシティ オブ テキサス システム ボード オブ リージェンツ Ａｐａｆ−１、ｃｅｄ−４ヒト相同体、カスパーゼ−３の活性化因子
IL133122A0 (en) 1997-06-18 2001-03-19 Genentech Inc Apo-2dcr polypeptides
US6004752A (en) * 1997-07-29 1999-12-21 Sarnoff Corporation Solid support with attached molecules
US6045753A (en) * 1997-07-29 2000-04-04 Sarnoff Corporation Deposited reagents for chemical processes
US20030175856A1 (en) * 1997-08-26 2003-09-18 Genetech, Inc. Rtd receptor
DK1009817T3 (da) * 1997-08-26 2010-01-18 Genentech Inc RTD-receptor
JP2002508962A (ja) 1998-01-15 2002-03-26 ジェネンテク・インコーポレイテッド Ａｐｏ−２リガンド
US20020136721A1 (en) * 1998-02-17 2002-09-26 Schwall Ralph H. Hepatocyte growth factor receptor antagonists and uses thereof
EP1086138B1 (en) 1998-06-12 2009-09-23 Genentech, Inc. Monoclonal antibodies, cross-reactive antibodies and method for producing the same
DE19836559A1 (de) 1998-08-12 2000-03-23 Antigen Gmbh Gefäß zur Entnahme von Blut
WO2000017356A2 (en) * 1998-09-18 2000-03-30 The Rockefeller University Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses therof
US6773911B1 (en) 1998-11-23 2004-08-10 Amgen Canada Inc. Apoptosis-inducing factor
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
EP2333049A1 (en) 1999-09-24 2011-06-15 ABT Holding Company Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
US7279294B2 (en) * 2000-04-03 2007-10-09 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services, Nih Tumor markers in ovarian cancer
IL152738A0 (en) 2000-05-10 2003-06-24 Mayo Foundation Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
EP1303293B1 (en) 2000-07-27 2008-12-03 Genentech, Inc. Sequential administration of cpt-11 and apo-2l polypeptide
PT1320542E (pt) 2000-08-08 2007-08-06 St Jude Childrens Res Hospital Ácidos nucleicos de estreptococo de grupo b, polipéptidos, composições terapêuticas e vacinas correspondentes
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
EP2336166A1 (en) 2000-10-12 2011-06-22 University Of Rochester Compositions that inhibit proliferation of cancer cells
US20050136431A1 (en) * 2000-11-03 2005-06-23 Oakley Robert H. Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
US7018812B2 (en) 2000-11-03 2006-03-28 Duke University Modified G-protein coupled receptors
US7163800B2 (en) * 2000-11-03 2007-01-16 Molecular Devices Corporation Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
WO2002047535A2 (en) * 2000-12-14 2002-06-20 Nyxis Neurotherapies, Inc. High throughput assay to detect inhibitors of the map kinase pathway
US7279324B2 (en) * 2001-01-23 2007-10-09 Duke University Nucleic acid encoding G-protein coupled receptor with modified DRY motif
RU2316337C2 (ru) 2001-04-24 2008-02-10 Мерк Патент Гмбх КОМБИНИРОВАННАЯ ТЕРАПИЯ, ИСПОЛЬЗУЮЩАЯ АНТИАНГИОГЕННЫЕ СРЕДСТВА И TNF-α
AU2002305452A1 (en) * 2001-05-08 2002-11-18 Emory University Regulating immine responses using dendritic cells
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
EP2335728A1 (en) 2001-05-11 2011-06-22 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
WO2002099069A2 (en) * 2001-06-05 2002-12-12 The Regents Of The University Of California Modulating neuronal outgrowth via the major histocompatibility complex class i (mhc i) molecule
US20090324612A1 (en) * 2001-06-05 2009-12-31 Kaufman Daniel L Modulating neuronal outgrowth via the major histocompatibility complex class i (mhc i) molecule
JP2005510249A (ja) 2001-07-20 2005-04-21 ザ ユニヴァーシティ オブ ジョージア リサーチファウンデーション， インク． 狂犬病に対するワクチン接種と中枢神経系における遺伝子治療のためのリン酸化部位において核蛋白質が変異した弱毒化狂犬病ウイルス
AUPR842501A0 (en) * 2001-10-23 2001-11-15 Epipop Pty Ltd A method for identification and development of therapeutic agents
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
EP2363405A1 (en) 2002-02-06 2011-09-07 Stasys Technologies, Inc. Anti-infarction molecules
EP1534729A2 (en) * 2002-02-26 2005-06-01 University of Utah Research Foundation Variants of nedd4l associated with hypertension and viral budding
US20030182669A1 (en) * 2002-03-19 2003-09-25 Rockman Howard A. Phosphoinositide 3-kinase mediated inhibition of GPCRs
US7317087B2 (en) 2002-03-25 2008-01-08 The Uab Research Foundation Members of the FC receptor homolog gene family (FCRH1-3, 6), related reagents, and uses thereof
CA2484628A1 (en) * 2002-05-07 2003-11-20 Becton, Dickinson And Company Collection assembly
US7290215B2 (en) * 2002-06-03 2007-10-30 Microsoft Corporation Dynamic wizard interface system and method
CA2489540A1 (en) 2002-06-14 2003-12-31 The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Office Of Technology Transfer Methods of treating and preventing colitis involving il-13 and nk-t cells
AU2003257181A1 (en) 2002-08-05 2004-02-23 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
US7514233B2 (en) 2002-09-26 2009-04-07 K.U. Leuven Research & Development Integrase cofactor
US7597936B2 (en) * 2002-11-26 2009-10-06 University Of Utah Research Foundation Method of producing a pigmented composite microporous material
WO2004048936A2 (en) * 2002-11-26 2004-06-10 University Of Utah Research Foundation Microporous materials, methods, and articles for localizing and quantifying analytes
AU2002953431A0 (en) * 2002-12-19 2003-01-09 Murdoch University BmpB Novel Nucleotide and Amino Acid Sequences and Diagnostic and Therapeutic Uses Thereof
EP1605847B1 (en) 2003-03-07 2009-09-16 Board Of Regents, The University Of Texas System Antibody-targeted photodynamic therapy
DK1718677T3 (da) * 2003-12-19 2012-07-09 Genentech Inc Monovalente antistoffragmenter egnede som terapeutiske midler
CA2553745A1 (en) 2004-01-21 2005-08-04 University Of Utah Research Foundation Mutant sodium channel nav1.7 and methods related thereto
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
CN101035808B (zh) * 2004-08-05 2012-10-31 健泰科生物技术公司 人源化抗c-met拮抗剂
US8000900B2 (en) 2004-09-21 2011-08-16 Microsoft Corporation Association-based predictions of pathogen characteristics
US20060095241A1 (en) * 2004-10-29 2006-05-04 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
WO2006037048A2 (en) * 2004-09-27 2006-04-06 The Uab Research Foundation Fc RECEPTOR HOMOLOG ANTIBODIES AND USES THEREOF
JP2008515813A (ja) 2004-10-06 2008-05-15 アグリ−バイオテック ピーティーワイ リミテッド 抗体産生方法
US8478535B2 (en) 2004-10-29 2013-07-02 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
AU2006236360B2 (en) 2005-04-15 2012-02-02 Genentech, Inc. HGF beta chain variants
AR053385A1 (es) 2005-05-12 2007-05-02 Novartis Ag Genes y proteinas novedosos de brachyspira hyodysenteriae y uso de los mismos para diagnostico y terapia
EP1931700B1 (en) 2005-05-19 2013-07-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES FUNCTIONAL EPITOPES OF STREPTOCOCCUS PNEUMONIAE PsaA ANTIGEN AND USES THEREOF
CA2619654A1 (en) * 2005-08-24 2007-03-01 Cell Matrix Combination therapies for inhibiting integrin-extracellular matrix interactions
AU2006302245A1 (en) * 2005-10-06 2007-04-19 Emthrax, Llc Methods and compositions relating to anthrax spore glycoproteins as vaccines
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
US20080107597A1 (en) * 2006-01-12 2008-05-08 Anaptys Biosciences, Inc. Isolation of antibodies that cross-react and neutralize rankl originating from multiple species
CA2637387A1 (en) 2006-01-18 2007-07-26 Simon Goodman Specific therapy using integrin ligands for treating cancer
US8470965B2 (en) * 2006-03-01 2013-06-25 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
EP1998792B1 (en) * 2006-03-01 2015-02-18 The University of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
ES2767626T3 (es) 2006-04-21 2020-06-18 Intervet Int Bv Especies de pestivirus
US20070254322A1 (en) * 2006-05-01 2007-11-01 Romaschin Alexander D Complement-based analyte assay
EP2104516B1 (en) 2006-11-01 2015-01-07 University of Rochester Methods and compositions related to the structure and function of apobec3g
US7492312B2 (en) * 2006-11-14 2009-02-17 Fam Adly T Multiplicative mismatched filters for optimum range sidelobe suppression in barker code reception
WO2008085794A2 (en) 2007-01-03 2008-07-17 Burnham Institute For Medical Research Methods and compositions related to clot binding compounds
ATE525484T1 (de) 2007-01-08 2011-10-15 Us Gov Health & Human Serv Slco1b3-genotyp
CN101588812A (zh) 2007-01-18 2009-11-25 默克专利有限公司 使用整联蛋白配体治疗癌的特异疗法和药物
MX338185B (es) 2007-01-25 2016-04-05 Dana Farber Cancer Inst Inc Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
FI20075059A0 (fi) 2007-01-29 2007-01-29 Valtion Teknillinen Allergeeniä sitovat monoklonaaliset IgE-vasta-aineet ja hypoallergeenit:tyypin l lgE:n ja allergeenin immunokompleksivuorovaikutus
JP5618549B2 (ja) 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤
CA2687024A1 (en) 2007-05-09 2009-02-19 Burnham Institute For Medical Research Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens
WO2008143676A1 (en) 2007-05-23 2008-11-27 The Uab Research Foundation Detoxified pneumococcal neuraminidase and uses thereof
PE20090368A1 (es) * 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
MX2010001381A (es) 2007-08-03 2010-09-14 Spirogene Pty Ltd Genes y proteinas de brachyspira hyodysenteriae y usos de los mismos.
PE20090499A1 (es) 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
MX2010001757A (es) 2007-08-14 2010-09-14 Ludwig Inst Cancer Res Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
WO2009026496A1 (en) * 2007-08-22 2009-02-26 University Of Southern California Grp78 and tumor angiogenesis
CA2697957A1 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
EP2682400B1 (en) 2007-08-28 2017-09-20 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
GB0720250D0 (en) 2007-10-17 2007-11-28 Univ Edinburgh Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof
FI20070853A0 (fi) * 2007-11-09 2007-11-09 Glykos Finland Oy Glykaania sitovat monoklonaaliset vasta-aineet
CA2706317C (en) 2007-12-03 2017-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Doc1 compositions and methods for treating cancer
EP2363407A1 (en) 2008-02-28 2011-09-07 Murdoch University Novel sequences of Brachyspira, immunogenic compositions, methods for preparation and use thereof
EP2260056A1 (en) * 2008-03-06 2010-12-15 Genentech, Inc. Combination therapy with c-met and her antagonists
AU2009227986C1 (en) 2008-03-27 2014-06-19 Murdoch University Novel sequences of Brachyspira, immunogenic compositions, methods for preparation and use thereof
NO2119726T3 (enExample) 2008-05-14 2015-05-23
AU2008360658B2 (en) 2008-08-15 2015-02-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services S0X9, prostaglandin D2 and retinoic acid for treating pigmentary conditions and melanoma
CA2736799A1 (en) 2008-08-25 2010-03-11 Burnham Institute For Medical Research Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
SI2172211T1 (sl) 2008-10-01 2015-03-31 Immatics Biotechnologies Gmbh Sestavek s tumorjem povezanih peptidov in zadevnih cepiv proti raku za zdravljenje glioblastoma (GBM) in drugih vrst raka
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
PT2376116E (pt) 2008-12-12 2016-02-24 Boehringer Ingelheim Int Anticorpos anti-igf
EP3059337B1 (en) 2009-01-15 2019-05-01 Adaptive Biotechnologies Corporation Adaptive immunity profiling and methods for generation of monoclonal antibodies
JP5822822B2 (ja) 2009-04-17 2015-11-24 ニューヨーク ユニバーシティ Ｔｎｆファミリー受容体を標的とし、ｔｎｆ作用を拮抗するペプチド、その組成物、方法および使用
NZ597339A (en) 2009-05-25 2013-10-25 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
WO2011020107A2 (en) 2009-08-14 2011-02-17 Georgetown University Compositions and methods for detection and treatment of breast cancer
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
US20110081293A1 (en) 2009-10-07 2011-04-07 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding lipid compounds
CN102612374A (zh) 2009-11-12 2012-07-25 霍夫曼-拉罗奇有限公司 提升树突棘密度的方法
CA2784145A1 (en) 2009-12-18 2011-06-23 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding compounds
WO2011084882A2 (en) 2010-01-05 2011-07-14 Contrafect Corporation Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
AU2011219029B2 (en) 2010-02-26 2017-02-02 Columbia University Methods and compositions for the detection and treatment of cancer involving miRNAs and miRNA inhibitors and targets
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
AU2011233753A1 (en) * 2010-03-31 2012-09-13 Anamar Ab Method to detect tissue degradation leading to inflammation
EP2569335B1 (en) 2010-05-14 2018-08-22 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
EA201300145A1 (ru) 2010-07-16 2013-12-30 Мерк Патент Гмбх Пептид для применения в лечении рака молочной железы и/или метастазов в кости
US9297813B2 (en) 2010-11-11 2016-03-29 Agency For Science, Technology And Research Targeting metabolic enzymes in human cancer
JP6483337B2 (ja) 2010-12-14 2019-03-13 ナショナル ユニヴァーシティー オブ シンガポール デングウイルス血清型１のｅタンパク質に対して特異性を有するヒトモノクローナル抗体およびその使用
US9051619B2 (en) 2011-03-25 2015-06-09 Florida Agricultural and Mechanical University (FAMU) Methods and compositions for prostate cancer metastasis
GB201107467D0 (en) 2011-05-05 2011-06-15 Univ Leuven Kath Novel treatment of pain
AU2012275233A1 (en) 2011-06-30 2013-11-28 Genentech, Inc. Anti-c-met antibody formulations
JP6170925B2 (ja) 2011-09-30 2017-07-26 サーコーティン ダイアグノスティックス エルエルシー 癌のマーカーとしてのｂｉｎ１の発現
US20130122005A1 (en) 2011-10-27 2013-05-16 Paul Adam Anticancer combination therapy
EP3608401A1 (en) 2012-07-05 2020-02-12 Ohio State Innovation Foundation Compositions and methods related to viral vaccines
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
US20140094383A1 (en) 2012-10-02 2014-04-03 Ohio State Innovation Foundation Tethered Lipoplex nanoparticle Biochips And Methods Of Use
WO2014085821A2 (en) 2012-11-30 2014-06-05 The Regents Of The University Of California Fully human antibodies and fragments recognizing human c-met
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
US10114015B2 (en) 2013-03-13 2018-10-30 Meso Scale Technologies, Llc. Assay methods
KR20230169418A (ko) 2013-03-13 2023-12-15 메소 스케일 테크놀러지즈, 엘엘시 개선된 분석 방법
WO2014201118A2 (en) 2013-06-11 2014-12-18 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment
TWI819228B (zh) 2013-08-05 2023-10-21 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八）
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
EP3502698A1 (en) 2014-05-05 2019-06-26 MicroBPlex, Inc. Media elaborated with newly synthesized antibodies and uses thereof
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
WO2015175856A1 (en) 2014-05-15 2015-11-19 Meso Scale Technologies, Llc. Improved assay methods
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
CA2954475C (en) 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
CA2967026A1 (en) 2014-11-07 2016-05-12 Mayo Foundation For Medical Education And Research Treatment of neonatal hypoxia including impairments or effects thereof
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
SI3616706T1 (sl) 2014-12-23 2021-12-31 Immatics Biotechnologies Gmbh Novi peptidi in kombinacija peptidov za uporabo v imunoterapiji proti hepatocelularnem karcinomu (HCC) in drugim oblikam raka
EP3265811B1 (en) 2015-03-02 2022-10-26 Sarcotein Diagnostics LLC 13+/17+ bin1 expression as a marker of cardiac disorders
PL3388075T3 (pl) 2015-03-27 2023-12-11 Immatics Biotechnologies Gmbh Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem różnych nowotworów
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
EP3919507A3 (en) 2015-07-01 2022-01-12 Immatics Biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MY198784A (en) 2015-07-06 2023-09-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
JP2018531625A (ja) 2015-09-11 2018-11-01 ナセント バイオテック インコーポレイテッド 脳への向上した薬物送達の方法
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
IL302705A (en) 2016-03-01 2023-07-01 Immatics Biotechnologies Gmbh Peptides, combinations of peptides, cell-based drugs for use in immunotherapy against bladder cancer and other types of cancer
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
AU2017234528B2 (en) 2016-03-16 2023-09-28 Nathan Bartlett Neutralizing monoclonal antibodies to IL-25 and uses thereof
SG11201808627RA (en) 2016-04-06 2018-10-30 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
TW202304970A (zh) 2016-08-26 2023-02-01 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
DK3523416T3 (da) 2016-10-05 2025-03-03 Univ Central Florida Res Found Inc Fremgangsmåder og sammensætninger relateret til nk-celle- og anti-pdl1-kræftbehandlinger
EP3559037A1 (en) 2016-12-22 2019-10-30 Wake Forest University Health Sciences Sirp-gamma targeted agents for use in the treatment of cancer
MA47367B1 (fr) 2017-01-27 2023-06-28 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
JP7346302B2 (ja) 2017-03-28 2023-09-19 オハイオ・ステイト・イノベーション・ファウンデーション ヒトｐｄ－１ペプチドワクチン及びその使用法
WO2018189152A2 (en) 2017-04-10 2018-10-18 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
TW201841934A (zh) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於治療癌症免疫治療的新穎肽及其肽組合物
CN111548406A (zh) 2017-04-10 2020-08-18 伊玛提克斯生物技术有限公司 用于癌症免疫治疗的肽及其肽组合物
BR112019028070A2 (pt) 2017-07-07 2020-07-14 Immatics Biotechnologies Gmbh peptídeos e combinações de peptídeos para uso em imunoterapia contra câncer de pulmão, incluindo cpcnp, cppc e outros cânceres
US10800823B2 (en) 2017-07-07 2020-10-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
JP2021506763A (ja) 2017-12-13 2021-02-22 ノース カロライナ ステート ユニバーシティＮｏｒｔｈ Ｃａｒｏｌｉｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ 化学療法剤とチェックポイント阻害剤とを含む組成物及び使用の方法
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202016131A (zh) 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
US20210260187A1 (en) 2018-06-29 2021-08-26 North Carolina State University In situ sprayed bioresponsive immunotherapeutic gel for post-surgical treatment
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (zh) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
CA3112212A1 (en) 2018-10-03 2020-04-09 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Covalent adaptor synnotch and chimeric antigen receptors (cars) for programmable antigen-targeting
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
EP4400840A3 (en) 2018-12-27 2025-02-12 University Of Utah Research Foundation Compositions and methods useful in detecting and treating multiple sclerosis and other demyelinating diseases
WO2020206233A1 (en) 2019-04-04 2020-10-08 Vanderbilt University Therapeutic antibodies for treating lung cancer
US11660330B2 (en) 2019-06-21 2023-05-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy
EP4031576A1 (en) 2019-09-18 2022-07-27 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
EP4093884A4 (en) 2020-01-24 2024-05-15 Vanderbilt University Methods for identification of ligand-blocking antibodies and for determining antibody potency
BR102020002165A2 (pt) 2020-01-31 2021-11-30 Fundação Oswaldo Cruz Anticorpo, seu uso, composição farmacêutica o compreendendo, método de diagnóstico de infecções fúngicas, kit de diagnóstico de infecções fúngicas e método para tratamento de infecções fúngicas.
CN115443171A (zh) 2020-05-08 2022-12-06 诺沃库勒有限责任公司 向多能干细胞施加交变电场的组合物和方法
WO2021237055A1 (en) 2020-05-21 2021-11-25 Ohio State Innovation Foundation Functional lipid derivatives and uses thereof
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202229312A (zh) 2020-09-29 2022-08-01 德商英麥提克生物技術股份有限公司 由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
DE102020125465A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
WO2022133092A1 (en) 2020-12-16 2022-06-23 Molecular Templates, Inc. Clinical methods for use of a pd-l1-binding molecule comprising a shiga toxin effector
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽
WO2025040598A2 (en) 2023-08-18 2025-02-27 Immatics Biotechnologies Gmbh Peptides displayed by mhc for use in immunotherapy against different types of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138213A (en) * 1974-05-20 1979-02-06 Technicon Instruments Corporation Agglutination immunoassay of immune complex with RF or Clq
US4169138A (en) * 1974-05-29 1979-09-25 Pharmacia Diagnostics Ab Method for the detection of antibodies
SE441042B (sv) * 1976-09-08 1985-09-02 Pharmacia Diagnostics Ab Sett att pavisa rheumatoida faktorer
SE441041B (sv) * 1976-09-08 1985-09-02 Pharmacia Diagnostics Ab Sett vid pavisning av rheumatoida faktorer
JPS5344622A (en) * 1976-09-30 1978-04-21 Mochida Pharm Co Ltd Immunologically measuring method
GB1590524A (en) * 1976-11-24 1981-06-03 Nat Res Dev Assay of immune complexes
GB1592450A (en) * 1976-12-10 1981-07-08 Technicon Instr Biological analysis
US4210622A (en) * 1977-09-07 1980-07-01 National Research Development Corporation Kit for assay of immune complexes
GB2013211B (en) * 1978-01-26 1982-06-30 Technicon Instr Immunoassays using f(ab')2 fragments
GB2013688B (en) * 1978-01-26 1982-06-30 Technicon Instr Insolubilised proteins and immunoassays utilising them
DE2840847A1 (de) * 1978-09-20 1980-04-03 Behringwerke Ag Verfahren zum nachweis und zur bestimmung komplementbindender antikoerper

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984000421A1 (fr) * 1982-07-16 1984-02-02 Otsuka Pharma Co Ltd Procede d'analyse de complexe immun specifique d'antigene associe a des tumeurs
JPH02502586A (ja) * 1987-12-10 1990-08-16 ブリテツシユ・テレコミユニケイシヨンズ・パブリツク・リミテツド・カンパニー 光学装置

Also Published As

Publication number Publication date
US4342566A (en) 1982-08-03
WO1981002469A1 (en) 1981-09-03
EP0046786A4 (en) 1982-07-13
EP0046786A1 (en) 1982-03-10

Similar Documents

Publication Publication Date Title
FR2492251B3 (enExample)
FR2472931B1 (enExample)
FR2473337B1 (enExample)
JPS57500207A (enExample)
DE3153253A1 (enExample)
CH655478B (enExample)
FR2490032B1 (enExample)
CH636493A5 (enExample)
FR2488285B1 (enExample)
FR2490188B3 (enExample)
DE3050577T1 (enExample)
FR2473496B1 (enExample)
GR73124B (enExample)
JPS57501691A (enExample)
DE3050253T1 (enExample)
CH655498B (enExample)
FR2473201B3 (enExample)
FR2473474B1 (enExample)
FR2473038B1 (enExample)
CH655579B (enExample)
FR2472923B1 (enExample)
CH632384GA3 (enExample)
FR2473238B1 (enExample)
FR2467999B2 (enExample)
FR2473492B1 (enExample)